Searchable abstracts of presentations at key conferences in endocrinology

ea0104S7.2 | Tricky Pituitary Cases | SFEIES24

Cyclical cushing’s syndrome

Isand Kristina

Cyclical Cushing’s Syndrome (CS) is a rare and complex disorder, accounting for approximately 14-18% of all CS cases. It is characterized by repeated episodes of cortisol excess in blood, saliva, and/or urine, interspersed with periods of normal or even low cortisol levels, observed on at least 2-3 separate occasions. The duration of each hypercortisolemic episode can vary widely, lasting from days to years, and may occur at regular or irregular intervals. This condition ...

ea0074ncc5 | Highlighted Cases | SFENCC2021

Grave’s orbitopathy – Metastatic breast cancer presenting as orbitopathy, not previously recorded in the endocrine literature

Isand Kristina , Wass John , Norris Jonathan , Heleen Noor Inger

Case history: A 67-year-old lady was referred to an endocrinologist for autoimmune hypothyroidism diagnosed in 2004. A treatment combination of levothyroxine and liothyronine was used. She had a history of recurrent metastatic ER-positive HER-2 negative lobular breast cancer with liver and bony metastatic involvement. She commenced with Letrozole (aromatase inhibitor) and Palbociclib (CDK inhibitor), later Fulvestrant (antioestrogen) and Crizotinib (tyrosine kinase inhibitor)....

ea0086p238 | Neuroendocrinology and Pituitary | SFEBES2022

Anticoagulation practice for venous thromboembolism prophylaxis in patients with Cushing’s Syndrome - a Society for Endocrinology survey of UK Centres

Isand Kristina , Plummer Zoe E , Volke Vallo , Newell-Price John , Wass John , Pal Aparna

Background: Cushing’s syndrome (CS) is estimated to have a 10-fold increased risk of venous thromboembolism (VTE) compared with the normal population with VTE accounting for 3.6-11% deaths in CS patients. There are no specific guidelines for VTE prophylaxis in CS other than that it should be considered given the increasingly recognised risk.Methods: Via the Society for Endocrinology, we surveyed current VTE anticoagulation practice across UK Endocri...

ea0090oc3.6 | Oral Communications 3: Pituitary and Neuroendocrinology 1 | ECE2023

Venous thrombotic events (VTE) across ERCUSYN: details of these VTE’s and do centres anticoagulate on a routine bases?

Isand Kristina , Feelders Richard , Brue Thierry , Toth Miklos , Deutschbein Timo , Reincke Martin , Krsek Michal , Vives Alicia Santos , Demtroder Frank , Chabre Olivier , J. Strasburger Christian , Wass John , Webb Susan M , Maso Ana Aulinas , Volke Vallo , Valassi Elena

For all ERCUSYN investigatorsBackground: Patients with Cushing’s syndrome (CS) have an increased risk of developing venous thromboembolic complications. There is currently no standard practise for thromboprophylaxis in CS patients.Aim: To study the details of VTE in patients included in The European Registry on Cushing’s syndrome (ERCUSYN) and study various thromboprophylaxis protocols used among the centres where VTE&#14...

ea0086p92 | Neuroendocrinology and Pituitary | SFEBES2022

Natural history of non-functioning pituitary microadenomas – results from the UK NFA consortium

Hamblin Ross , Fountas Athanasios , Lithgow Kirstie , Loughrey Paul Benjamin , Bonanos Efstathios , Khalid Shinwari Shah , Mitchell Kirsten , Shah Syed , Grixti Lydia , Matheou Mike , Isand Kristina , McLaren David , Surya Ashutosh , Zubair Ullah Hafiz , Klaucane Katarina , Jayasuriya Anuradha , Bhatti Sumbal , Mavilakandy Akash , Ahsan Masato , Mathew Susan , Hussein Ziad , Jansz Thijs , Wunna Wunna , Ayuk John , Abraham Prakash , Drake William , Brooke Antonia , Baldeweg Stephanie E. , Sam Amir H. , Martin Niamh , Higham Claire , Reddy Narendra , Ahluwalia Rupa , Newell-Price John , Vamvakopoulos Joannis , Krishnan Amutha , Lansdown Andrew , Murray Robert D , Pal Aparna , Bradley Karin , Mamoojee Yaasir , Purewal Tejpal , Panicker Janki , Marie Freel E , Hasan Faisal , Kumar Mohit , Jose Biju , Hunter Steven , Karavitaki Niki

Background: The published data on the natural history of (presumed) non-functioning pituitary microadenomas (micro-NFAs) is possibly compromised by small sample sizes, short follow-up and inclusion of cases with other pathologies in the analyses.Objective: To clarify the long-term outcomes of micro-NFAs in a large cohort of patients.Methods: We conducted a multi-centre, retrospective, cohort study involving 22 UK endocrine departme...